Background: Breast cancer accounts for 7% of female cancer deaths, usually attributable to metastasis. While surgery is a mainstay of treatment, perioperative interventions may influence risk of metastasis during breast tumour resection. Amide local anaesthetics influence cancer cell biology via numerous mechanisms in vitro, but in vivo data is lacking. We aimed to test the hypothesis that perioperative lidocaine reduces pulmonary metastasis after inhalation and i.v. anaesthesia in the 4T1 murine breast cancer model. Methods: 4T1 Cancer cells were injected into the mammary fat-pad of immunocompetent BALB/c female mice. After 7 days, the resultant tumour was excised under either sevoflurane or ketamine/xylazine anaesthesia with or without perioperative i.v. lidocaine (1.5 mg kg À1 bolus followed by 25 min infusion 2 mg kg À1 h
reduced pro-inflammatory and angiogenic cytokine expression in animals without metastasis which received lidocaine with sevoflurane. Conclusions: In this 4T1 murine model of breast cancer, lidocaine decreased pulmonary metastasis when combined with sevoflurane anaesthesia, perhaps via anti-inflammatory and anti-angiogenic effects. It had no such effect in mice given ketamine anaesthesia.
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Editor's key points
The effect of lidocaine on metastasis after breast cancer resection and either sevoflurane or ketamine/xylazine anaesthesia was studied in mice. Sevoflurane anaesthesia with lidocaine resulted in lower cancer cell colony counts and fewer animals with metastases in the lung compared with sevoflurane alone. Lidocaine did not have this effect when combined with ketamine/xylazine anaesthesia. In this breast cancer mouse model, lidocaine combined with sevoflurane was of benefit in reducing metastases after surgical resection.
Cancer is a leading cause of death and morbidity worldwide and 1,2 breast cancer is one of the most common of all cancers, affecting one in eight women. 2 Metastatic disease is the most important cause of cancer-related death, especially in breast cancer. 3 While tumour excision surgery is a mainstay of cancer management, some minimal residual cancer or circulating tumour cells remain. 4 The immediate intraoperative period of tumour excision may be a uniquely susceptible critical period, for the formation and survival of metastasis or its resistance and elimination. 3, 4 A number of perioperative factors may shift the balance towards metastatic progression of circulating tumour cells, either by direct effects of anaesthetic or analgesic agents, or by indirect effects on the immune system or the surgical stressinflammatory response. 4, 5 Initially, a beneficial role for regional anaesthesia in attenuating cancer metastasis was suggested, by attenuating the surgical stress response and preserving perioperative innate immune function. 3,6e8 More recently, compelling in vitro data has emerged that amide local anaesthetics, of which the prototype is lidocaine, directly inhibit cancer cell metastatic function by a variety of specific mechanisms, in addition to inhibition of sodium ion channels.
9e13
There is nonetheless a dearth of in vivo evidence of the effect of amide local anaesthetics on tumour models, a deficiency highlighted in a recent Cochrane Review. 14, 15 A recent inoculation mouse model of hepatocellular carcinoma suggested a beneficial role for lidocaine by enhancing caspasedependent cancer cell apoptosis via the mitogen-activated protein kinase pathway, a signalling mechanism which can lead to uncontrolled growth in many tumours. 16 Inhalational anaesthesia remains the most frequent technique of maintenance of general anaesthesia in modern clinical practice. In vitro data on the effects of inhalation agents on cancer cell biology indicate potentially harmful effects in promoting tumour cell proliferation and migration and increasing the expression of metastasis-enhancing genes. 17 Moreover, ketamine as an i.v. anaesthetic is used as induction agent in haemodynamically unstable patients and, increasingly, as an adjunctive analgesic in acute postoperative pain. 18 In vitro data suggests it may also have potentially detrimental effects on cancer cell biology. 3 However, there are no in vivo data on the effect of lidocaine on these anaesthetic techniques for tumour excision in breast cancer. Therefore, we tested the hypotheses that lidocaine attenuates cancer metastasis: (a) after inhalation sevoflurane anaesthesia, and (b) after ketamine-xylazine anaesthesia, during surgical tumour excision in the 4T1 murine model of breast cancer.
Methods
This research work was conducted in accordance with EU directive on animal studies (EU2010/63) and adhered to the Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines on reporting of the use of animals in research. 19 
Tumour model
The BALB/c 4T1 murine breast tumour model is a widely used in vivo breast cancer syngeneic model with numerous advantages, including spontaneous metastatic disease in a similar pattern to human disease. Moreover, the resistance of the 4T1 cell to 6-thioguanine enables the quantification of metastatic cells in distant organs using tissue culture techniques. 20 We adapted the standard BALB/c 4T1 model to perform the primary tumour resection in the pre-metastatic phase of tumour progression. To optimise this model to study the role perioperative agents may play in the surgical treatment of premetastatic disease, we undertook a pilot study which suggested that spontaneous metastasis of tumour cells occurs approximately 8 days after inoculation of 4T1 tumour cells into the mammary fat pad. 21 By operating on Day 7, before spontaneous metastasis occurred, we were better able to study the potential role perioperative agents play in inhibiting the seeding of metastatic cells to distant organs.
Cell culture
4T1 Cancer cells were grown in Roswell Park Memorial Institute culture medium (RPMI) with prophylactic penicillin/ streptomycin antibiotic and foetal calf serum at 37 C, 5% CO 2 in culture flasks as per protocol. 20 The cells were removed, concentrated by centrifugation, counted, re-suspended in RPMI at a concentration of 1Â10 6 cells ml À1 and tested to ensure >80% cell viability (Countess Automated Cell Counter, Invitrogen, Carlsbad, California, USA).
Test animals
The test animals, 8-to 10-week-old female BALB/c mice, were purchased specifically for this study (Charles River laboratories, Edinburgh, Scotland). They underwent 5-day acclimatisation before enrolment in the study and were housed in standardised conditions throughout, in individually ventilated cages with sawdust bedding and enrichment (n¼4 per cage), within the specific pathogen-free barrier at the Biomedical Facility, University College Dublin, Dublin, Ireland. They had unrestricted access to food and water and were maintained in a 12-h light/dark cycle at standard temperature and humidity. Mice were randomised (blocked stratified randomisation with one of each treatment group assigned to an animal from within each housing cage) into four experimental groups with each animal being an individual unit distributed across the cohort housing and treatment groups (Figs 1 and 2 ). The groups were as follows: Experimental groups consisted of 22 animals each (total 88). One animal in each of the sevoflurane groups and two animals in each of the ketamine-xylazine groups had anaesthetic mortality (Fig. 1 ). Mice were randomised, using a random numbers table with even numbers indicating sevoflurane allocation (n¼44) and odd numbers indicating ketamine-xylazine allocation (n¼44). Within each group, a table of random numbers was used again, with even numbers indicating a perioperative lidocaine infusion, odd numbers indicating no lidocaine infusion. A blocked study design established the evaluation of equal numbers from each anaesthetic regimen experimental group across each surgical day. Study protocols were approved by the University College Dublin Animal Research Ethics Committee and authorised by the Health Products Regulatory Authority of Ireland.
Establishing the tumour
On study Day 0, the mice were inoculated with 2.5Â10 4 4T1
tumour cells suspended in 0.025 ml of RPMI s.c. with a 30-gauge hypodermic needle into the fat pad of the lower right inguinal mammary gland. 20 Tumour growth was monitored daily using electronic callipers and the tumour diameter was calculated taking the tumour diameter as the square root of the length multiplied by the width. Mouse welfare was monitored daily by assessing weight, body condition, behaviour, and the mouse "grimace scale". 22 
General anaesthesia
On Day 7 post-inoculation of tumour cells, the tumour was excised under general anaesthesia using the allocated anaesthetic regimen. The inhaled anaesthetic sevoflurane (AbbVie, Chicago, Illinois, USA) was delivered at a concentration of 5% in 50% oxygen into an induction box. After loss of pedal withdrawal response to a nociceptive stimulus, anaesthesia was maintained with 3% sevoflurane in 50% oxygen using an open face mask. The injectable anaesthesia regimen was administered via an i.p. injection of ketamine (100 mg kg À1 )
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Day 7
Resec on of tumours 5Â10 4 ) were injected into the mammary region of n¼88 BALB/C mice. On Day 7, the resulting tumours were resected under general anaesthesia, either inhalational (sevoflurane), n¼44, or injectable (ketamine and xylazine), n¼44, half the mice from each group were randomised to the treatment group which received an i.v. lidocaine infusion (1.5 mg kg À1 bolus followed by 25 min 2 mg kg À1 h À1 infusion) or a control group which received an equal volume of 0.9% NaCl solution. On Day 21, the mice were culled, and blood, lung, and liver samples were collected for investigation; one animal died under anaesthesia from each of the sevoflurane groups while two died in each of the ketamine xylazine groups.
and xylazine (0.1 mg kg À1 ), while 50% oxygen was also administered via a face mask. Depth of anaesthesia was deemed adequate for surgery when loss of righting reflex, loss of palpebral reflex, and absent pedal withdrawal response to pain were confirmed. In the inhalational groups, anaesthesia was reversed by switching off sevoflurane delivery after 30 min. In the ketamine-xylazine groups, after surgery and 30 min after initial injection of anaesthesia, atipamezole (2 mg kg À1 ) was administered s.c. 30 min after initial anaesthetic injection to reverse the effect of the xylazine (alpha-2 agonist).
Excision of the tumour
The surgical area was shaved and prepared with chlorhexidine gluconate 20 mg ml À1 and isopropyl alcohol 0.70 ml ml
À1
(ChloraPrep®, CareFusion, Basingstoke, England). I.v. access for administration of lidocaine or saline (see next section) was established using a 26-gauge i.v. cannula (Hospira, Lake Forest, Illinois, USA) sited in a lateral tail vein. The tumour was excised using a standard surgical aseptic technique and the surgical site was closed using interrupted 6.0 polypropylene sutures (Ethicon, Somerville, New Jersey, USA). The duration of infusion was standardised to 25 minutes after which time the i.v. cannula was removed.
Administration of analgesics and lidocaine
Before tumour excision, analgesics (paracetamol 200 mg kg ) at 12-h intervals over 2 days. Although the s.c. route of administration would not be used clinically, it is well established as a convenient and effective technique of achieving therapeutic drug levels in this animal model. Supplemental doses were given as required based on the GRIMACE scale as an indicator of pain. 22 Provision for breakthrough pain treatment with opiate analgesia (buprenorphine 0.05 mg kg À1 s.c.) was incorporated into the protocol, but no animals required this.
Quantification of distant metastasis
The primary end point was the number of pulmonary metastatic colonies. Secondary end points were the presence or absence of any pulmonary metastasis, liver metastatic colony counts, and the presence or absence of local recurrence of breast tumour. On Day 21, the mice were culled by cervical dislocation and decapitation without anaesthesia or sedation, at which time blood, lung and liver samples were obtained using an aseptic technique with care to prevent cross contamination. Lung samples were treated with 5 ml collagenase IV in Hank's balanced salt solution (HBSS) (~125 units ml À1 ; SigmaeAldrich, St. Louis, Missouri, USA), and liver samples were treated with collagenase I (~125 units ml À1 ; SigmaeAldrich) and hyaluronidase (~500 units ml À1 ; SigmaeAldrich) in 5 ml HBSS. The samples were then filtered through a cell strainer to isolate cells and cultured in the presence of 60 mM 6-thioguanine (SigmaeAldrich) at 37ºC in air with 5% CO 2 for 14 days. Cells were fixed using 100% methanol and stained for 5 min using 0.03% wv À1 methylene blue. Metastatic colonies formed are the result of a single or small number of 4T1 cells. Culture plates were examined by two researchers, blinded to the experimental treatment groups and to each other's interpretation, and the number of colonies was counted using gross appearance using low magnification microscopes. 20 
Blood analysis
Posthumous blood samples were collected from the mice by decapitation and collection from the neck. These samples were analysed according to whether animals had metastases or not within each treatment arm. Serum samples were prepared by centrifugation and 10 ml of serum was diluted in phosphate buffered saline to a final volume of 50 ml. Samples were analysed using a mouse cytokine antibody array (QAM-CYT-2-1, RayBiotech, Norcross, GE, USA) according to the manufacturer's protocols. A fluorescent laser scanner (GenePix 4000B) was used to scan the arrays at 550 nm excitation 570 nm emission. Emissions were quantified using the GenePix 4000B inbuilt software and normalised to the positive control spots on each array for comparison. The intra-and inter-assay variability was 7.5% and 19%, respectively (coefficient of variation, n¼6).
Statistical analysis
A sample size calculation was undertaken based on a 50% reduction in colony count which, based on previous studies with this model, was taken as oncologically and probably clinically meaningful, and a standard deviation (SD) of 35, n¼20 animals were required in each group to achieve 80% power.
Allowing for unexpected death, we included 22 animals in each of the proposed study groups. Colony count data was subjected to the D'Agnostino and Pearson omnibus normality test and found not to be normally distributed. Therefore, the ManneWhitney U test was used for non-parametric independent samples comparisons. Cytokine expression data were normally distributed and analysis of variance with post hoc Bonferroni correction for multiple testing was undertaken for comparison between groups. For comparison of two independent normally distributed variables, the unpaired Student's t-test was used. Categorical data was assessed by c 2 analysis of contingency tables with Yates' correction. Results are given as median and inter-quartile range and full range or mean and SD as appropriate, unless otherwise indicated. Probability values of <0.05 were considered statistically significant.
Results
Animal baseline characteristics
There was no significant difference in the tumour sizes between the groups at the time of resection (Fig. 3) . Tumour diameter at surgical excision was 2.27 mm (0.64 mm) in the sevoflurane with lidocaine group vs 2.21 mm (0.67 mm) in the sevoflurane control group, P¼0.9, and 2.65 mm (0.41 mm) in the ketamine/xylazine with lidocaine group vs 2.27 mm (0.47 mm) in the ketamine/xylazine control group, P¼0.2. The weight of the animals, which is an indicator of animal welfare, was broadly static throughout the experiment and similar in the four groups (Fig. 4) . One animal died under anaesthesia from each of the inhalational anaesthesia groups. In the ketamine/xylazine groups, two animals from each group died under anaesthesia. The remaining 82 animals were included in the analysis (Fig. 1) . 
Effect of lidocaine with sevoflurane anaesthesia
When combined with sevoflurane anaesthesia, i.v. lidocaine significantly reduced the pulmonary metastatic burden in mice with breast cancer undergoing surgical resection (Fig. 5) . Mice receiving i.v. lidocaine had a significantly lower overall number of pulmonary metastatic colonies compared with sevoflurane alone (P¼0.02, Fig. 5A ). Lidocaine exposure also resulted in a lower total number of metastatic colonies in mice who had any detectable pulmonary metastasis; 29% (n¼21) compared with 52% (n¼21, P¼0.04). When the mice with no pulmonary metastasis were excluded, markedly lower numbers of pulmonary metastatic colonies were observed with lidocaine treatment (P<0.01, Fig. 5B ). There was no significant difference in the median (range) liver colony counts; 0 (0e370) compared with 1.5 (0e130), P¼0.89. There was also no difference in the rate of local tumour recurrence between animals receiving sevoflurane plus lidocaine and animals receiving sevoflurane anaesthesia alone; 5% (n¼21) and 19% (n¼21), respectively (P¼0.08).
Effect of lidocaine with ketamine and xylazine anaesthesia
When combined with ketamine and xylazine anaesthesia, i.v. lidocaine administration had no protective effect in terms of overall colony count (P¼0.43, Figure 6A ). There was a significant increase in the number of animals with detectable pulmonary metastasis in the lidocaine group, (100%, n¼20) compared with the control group (50%, n¼20), P<0.01. When animals with no detectable pulmonary metastasis were excluded, there was no significant difference in pulmonary colony counts (P¼0.27, Fig. 6B ). There was also no significant difference in the liver colony counts: ketamine and xylazine with lidocaine, 225 (0e2010; n¼20) compared with ketamine and xylazine controls 67.5 (0e345; n¼20), P¼0.12. Local recurrence was similar in the two groups, 0% (n¼20) and 10% (n¼20), P¼0.24.
Cytokine analysis
A large number of cytokines implicated in pro-inflammatory or pro-angiogenesis effects were significantly attenuated by lidocaine in the groups receiving sevoflurane anaesthesia (Supplementary Table S1 ). Significantly lower concentrations of pro-inflammatory mediators derived from macrophages and neutrophils were detected in the lidocaine group; these included tumour necrosis factor a and interleukin (IL)-6, which may be involved in disrupting endothelial barriers and promote other inflammatory cell infiltration. 23 Cytokines derived from CD4 þ lymphocytes were also seen to be significantly reduced by lidocaine in the sevoflurane groups including interferon-g, IL-2, IL-4, IL-10, and IL-17, which play a role in endothelial disruption and angiogenesis, and have effects on the differentiation and cytotoxicity of immune cells. 24e26 In the ketamine and xylazine groups, however, this generalised anti-inflammatory effect was not observed (Supplementary  Table S2 ).
Discussion
We investigated perioperative i.v. lidocaine on metastasis using the well-established 4T1 syngeneic murine model of breast cancer. Our main findings were that lidocaine reduced the numbers of animals exhibiting any pulmonary metastasis and also the number of pulmonary metastatic colonies when used in conjunction with sevoflurane anaesthetic. However, the opposite was observed in the animals receiving the i.v. anaesthetic combination of ketamine and xylazine, where significantly more animals in the lidocaine treatment arm had detectable pulmonary metastasis. We chose to use lidocaine for this study. Lidocaine is the prototype amide local anaesthetic, is licensed for i.v. human use, and has a relatively high therapeutic index. Furthermore, it has proved safety, tolerability, and anti-inflammatory benefit during perioperative i.v. administration. 27 It has other perioperative benefits including reduced persistent postoperative pain after breast cancer surgery and enhanced gut motility in colorectal surgery patients, and is an inexpensive and widely available drug. 28 Amide local anaesthetics, including lidocaine, directly inhibit cancer cell metastatic function, by a variety of specific mechanisms, in addition to inhibition of sodium ion channels. 9e13 Lidocaine infusion was limited to 25 min in our studies because that was the approximate duration of anaesthesia. It was impractical to continue an infusion for longer, which would be feasible in the clinical setting. It is therefore plausible to consider designing randomised clinical trials to evaluate its effect on long-term oncological outcomes after cancer surgery. It is plausible that lidocaine has different interactive effects when combined with different anaesthetic agents as seen in our experiment. In a xenograft mouse model using HepG2 (human hepatocellular carcinoma) cells, lidocaine significantly inhibited primary tumour growth in vivo and influenced apoptosis regulation in vitro. 16 In that study, mice received repeated i.p. injections of lidocaine, which resulted in significantly reduced primary tumour diameters. In contrast to our study, the primary tumours were not resected, nor were the mice anaesthetised at any point. In our study, we observed higher rates of animals with evidence of pulmonary metastasis in the ketamine/xylazine with lidocaine group compared with controls, which may be because of the interaction of the anaesthetic agents with lidocaine. Ketamine has known deleterious effects on cancer metastasis, potentially via inhibiting immune function. Indeed, we have observed no change in pro-inflammatory or pro-angiogenic factors when lidocaine was used with ketamine anaesthesia, suggesting that ketamine attenuates any anti-inflammatory and antiangiogenic effect of lidocaine observed in the sevoflurane anaesthesia groups. I.P. ketamine (100 mg kg À1 ) combined with xylazine (0.1 mg kg
À1
) is a commonly used murine anaesthetic. 29 While it is appropriate to consider the translational applicability of administering i.p. drugs, which obviously never occurs in the clinical cancer setting, this technique is routine in animal models of this type and achieves appropriate drug delivery at clinically relevant levels. Similarly, although 50% O 2 concentration could be considered high in some clinical settings, it is commonly used, even in patients without respiratory dysfunction. Ketamine is an N-methyl-D-aspartate antagonist and xylazine is an alpha-2 agonist. Ketamine and lidocaine in combination have been shown to have a synergistic effect on the anaesthetic effect of ketamine and a reduction in the lethal dose. 30 While 4T1 cells are not known to express adrenoceptors, alpha-2 stimulants have been shown to promote cancer progression in the 4T1 tumour model, therefore the xylazine/atipamezole combination may be a confounding factor in addition to the sympathomimetic and other prometastatic properties of ketamine. 31 We speculate that the detrimental clinical effects we observed in those mice that received a combination of lidocaine with ketamine and xylazine anaesthesia, in terms of marked cardiorespiratory compromise (reduced respiratory rate/agonal breathing and pallor), delayed emergence from general anaesthesia (return of righting reflex) and altered thermoregulation (prolonged piloerection), may have further led to a pro-metastatic environment offsetting any potential anti-metastatic benefit of lidocaine witnessed in the inhalational groups. 3, 30 While propofol is the most widely used injectable anaesthetic agent in human clinical practice and may have some intrinsic anti-metastatic effects, it is poorly suited for murine anaesthesia, as it does not induce safe, adequate, and reproducible anaesthesia in mice when given either via the i.v. or i.p. route. 4, 32, 33 Analysis of serum samples from a small number (n¼3) of animals with and without metastasis in our studies suggests that lidocaine attenuated levels of some measured cytokines, many of which have pro-inflammatory and pro-angiogenesis associations, in animals with and without metastatic disease where a sevoflurane technique was used. This may be attributable to the known anti-inflammatory effects of lidocaine. When used in conjunction with ketamine/xylazine anaesthesia, however, lidocaine had no apparent effect on the expression of most cytokines in the presence or absence of metastasis.
We chose the 4T1 mouse model of breast cancer because as it is a syngeneic model of breast cancer in immunocompetent animals, which closely resembles human disease in terms of anatomical location and spread. 34 In addition, the superficial location of the tumour makes it readily amenable to resection, as is the case in breast cancer where primary resection remains a mainstay of treatment. It is useful for the study of Stage IV breast cancer, and provides a model of aggressive disease with spontaneous metastasis occurring to lungs, liver, and brain, with proliferation of the metastatic tumours before and after surgical resection of the primary tumour. Being a syngeneic model, injection of 4T1 cells does not invoke an immune response in BALB/c mice therefore facilitating immunocompetent animal use. 35 Despite these advantages, no single in vivo model can truly replicate the complexity of human cancer progression. There are numerous alternative animal models of cancer. Such models include i.v. inoculation of cancer cells; whilst this model does have some attractive elements in terms of its ease to conduct and the speed of progression at which lung metastasis are generated, there are limitations. Orthotopic implantation better mimics human disease, as the cells must follow the biological steps required to form distant metastasis when compared with i.v. inoculation. 34 Gene expression may be altered by the mode of delivery. 36 Xenograft models, or injection of human cancer cells into other species, require immunodeficient mice, as immunocompetent mice would likely reject the cells. 37 Transgenic mice, where mice are genetically engineered to be susceptible to specific tumours, are better suited to establishing the potential role that genetic abnormalities may have on tumour development and progression. 37 Carcinogen-induced tumour models can be used for cancer research, however, these models frequently result in large discrepancies being observed between animals. 37 After our pilot study to define the optimal timeframe for surgery, the refinements we made to the 4T1 model for investigating perioperative agents on cancer progression have the potential to be widely adapted to examine the potential effects of a wide number of perioperative agents. 21 While maintaining all the benefits of the existing 4T1 model discussed above, our refinement of the model enables experiments to be performed and produce results in a relatively short timeframe, with fewer potential complications and minimal impact on animal welfare throughout the study.
In conclusion, this in vivo study into the potential role of perioperative lidocaine on breast cancer metastasis in this syngeneic murine model has shown that, in the setting of sevoflurane anaesthesia, lidocaine had a protective effect, significantly reducing the pulmonary metastatic burden. However, there was no significant decrease in metastasis observed when i.v. lidocaine was given in conjunction with the injectable anaesthetic combination of ketamine and xylazine.
Given mounting in vitro data and some compelling, though inconclusive, retrospective evidence in human studies, further in vivo studies of perioperative agents, such as propofol, corticosteroids, and analgesics are warranted. Should a protective effect be found in further animal studies, consideration should be given to undertaking a definitive prospective, randomised clinical trial to determine the effect of perioperative i.v. lidocaine during cancer surgery on long-term oncological outcomes.
